Cachexia is a common negative consequence of cancer and is often unrecognized. To assess cachexia, malnutrition assessment tools are used. This review discusses the advantages and disadvantages of the current malnutrition assessment tools and describes the requirements for a comprehensive cachexia assessment instrument and its implication for clinics and research.
Introduction
Cachexia from the Greek words kakos hexis, meaning bad condition, was already described by Hippocrates as a common consequence of cancer and other diseases. Cancer cachexia historically was most often defined by weight loss. Most cancer patients lose weight prior to diagnosis, and this loss often progresses during the course of their disease. For example, weight loss 10% was reported to occur in 38-45% of more than 1500 unselected cancer outpatients [1] .
Assessment, treatment or prevention of cachexia in cancer patients is paramount, as cachexia is associated with reduced effectiveness of anticancer treatments, increased risk of therapy-associated side-effects, reduced performance status, physical function and reduced quality of life [2 ] . Cachexia shortens survival and is responsible for the death of a substantial amount of cancer patients [3] .
Evolution of definitions
Cancer cachexia definition has evolved over time. To better understand current challenges of assessment this process is briefly summarized.
Measurement of weight loss is the common feature of all definitions. However, cut points range from 2% up to 20% without statistical justification [4 ] .
First anorexia or reduced intake has been added to weight loss. In the largest phase III studies, cancer cachexia was usually defined as weight loss (involuntary weight loss of 2% in 2 months or 5% in 6 months), anorexia (VAS >3/10, zero no problem, 10 maximal problem) or impaired oral nutritional intake (<75% than normal or <20 kcal/kg body weight) [5 ].
Fearon et al. [6] proposed adding systemic inflammation as a third factor to the definition, based on a study in 170 weight-losing pancreatic cancer patients. The simultaneous presence of three factors: weight loss more than 10%; low food intake less than 1500 kcal/day; and systemic inflammation, C reactive protein more than 10 mg/l has been shown to have prognostic and functional impact.
The SCRINIO (Screening Nutritional Risk in Oncology) Working Group proposed four stages of severity of cachexia based on weight loss of more than 10% or less than 10% and on the presence of the three symptoms: (anorexia, early satiety, or fatigue) [7] .
A proposed generic definition for cachexia/wasting includes weight loss with or without fat loss, and as additional criteria (three required for diagnosis) decreased muscle strength, reduced muscle mass, fatigue, anorexia, or biochemical alterations (anemia, inflammation, and low albumin) [8] .
New research shows that the underlying progressive muscle loss is the crucial factor, which accounts most for the adverse effects of cancer cachexia [9] . Therefore, the measurement of solely body weight loss may underestimate the frequency and impact of cachexia, namely patients who are overweight or even gain weight due to edema or growing tumor mass.
For cancer patients, several attempts to reach a common definition have been undertaken [10 ] . The most systematic approach applied systematic literature reviews and a formal Delphi process of 13 clinical cancer cachexia experts fulfilling the inclusion criteria [5 ].
The European Palliative Care Research Collaborative (EPCRC) defines cancer, cachexia as a multifactorial syndrome characterized by an ongoing loss of skeletal muscle mass (with or without loss of fat mass) that cannot be fully reversed by conventional nutritional support and leads to progressive functional impairment. The pathophysiology is characterized by a negative protein and energy balance driven by a variable combination of reduced food intake and abnormal metabolism.
According to the EPCRC Classification Cancer, cachexia is a continuum with three stages of clinical relevance encompassing precachexia, with early clinical and metabolic signs of cachexia; cachexia, with more than 5% loss of stable body weight in the last 6 months, or with a BMI less than 20 kg/m 2 and ongoing weight loss; and refractory cachexia, in which cachexia may be clinically refractory due to very advanced cancer (preterminal) or the presence of rapidly progressive cancer unresponsive to anticancer therapy.
Validated cachexia assessment tools based on the new definition and classification are not yet available. The consensus could agree on five domains, as follows, which should be encompassed in cancer cachexia assessment:
(1) Stores depletion (2) Muscle mass and strength (3) Anorexia or reduced food intake (4) Catabolic drivers (5) Functional and psychosocial effects
Malnutrition and cachexia
Cachexia has to be differentiated conceptually and clinically from malnutrition. Malnutrition is defined as the condition when the human body does not receive the right amount of nutrients (energy, proteins, minerals and vitamins) and can occur in healthy individuals. Malnutrition is characterized by weight loss based on loss of fat mass in the first instance and can be reversed with nutritional therapy by definition.
In contrast, cachexia is characterized by the presence of an underlying disease, which increases catabolism via systemic inflammation among other factors and causes primarily muscle loss. Per definition, nutritional support only is not sufficient to reverse cachexia.
Multimodal interventions for cachexia require assessment
Cachexia treatment should be stratified according to stage. In precachectic patients, the focus is on monitoring and prevention. In cachectic patients, the full range of therapeutic actions should be applied, and a more specific cachexia phenotyping could help to better tailor treatment to these patients. Cachexia treatment encompasses the correction secondary causes of impaired nutritional intake [secondary nutrition impact symptom (S-NIS)]. Appropriate nutritional support, ranging from counselling to total parenteral nutrition is provided. The best treatment of the underlying disease should be performed with regards to prevention and treatment of therapyrelated side-effects. Specific anticachexia medications are supplemented by interventions to improve physical activity and function [11 ] .
In refractory cachexia, the burden of pharmacological and nutritional interventions would outweigh potential benefits; the focus is on alleviating suffering and avoiding complications, which often includes discontinuation of anticancer or anticachectic treatment. The main focus is on psychosocial support and end of life care [12 ] .
Cachexia therapy must be multimodal:
(1) Antineoplastic tumor therapy to reduce catabolic drive (2) Pharmacological anti-cachexia interventions to reduce catabolic drive, improve appetite regulation, or to influence muscle mass and function. Key points Cachexia is a common consequence of cancer, which limits quality and length of life. Cachexia assessment includes not only weight loss and anorexia, but also encompasses five domains as follows: stores including fat and muscle strength, intake and associated symptoms, catabolism including inflammation and tumor activity and patients' physical and psychosocial functions. Cachexia can be classified in the stages precachexia/ cachexia/refractory and cachexia treatment should be stratified to cachexia stage. Validation of tools will improve assessment and treatment.
(4) Basic physical activity instructions to promote anabolic stimuli to the muscle (5) Psychosocial interventions and emotional support to encourage and support patients/proxies
Implication of the new cachexia definition and classification on assessment
An up-to-date cachexia assessment tool should be helpful as a screening tool to detect patients with cancer cachexia, assess the set of key variables to classify and phenotype cancer cachexia and act as a clinical decision guiding instrument, suitable to improve outcomes.
Today there are no common assessment tools or validated measurements for all of these domains. Due to the lack of a specific cachexia assessment tool, malnutrition assessment tools are used in daily practice.
Malnutrition assessment tools
Researchers and Nutrition Societies developed various malnutrition assessment tools whether for screening purposes or for comprehensive nutritional assessment [13] . These instruments are used for all kinds of diseases, few are specific for cancer. Most malnutrition assessment tools classify patients as malnourished, at risk for malnutrition or not, and link actions in terms of monitoring or treatment to these groups. Malnutrition assessment tools are intended to help to decide whether and to what extent nutritional support should be initiated. The most commonly used malnutrition assessment tools are patient-generated subjective global assessment (PG-SGA), mini nutritional assessment (MNA), malnutrition-screening tool (MST), malnutrition universal screening tool (MUST), and nutritional risk screening-2002 (NRS-2002).
Patient-generated subjective global assessment
The PG-SGA is an assessment tool for nutritional risk in cancer. A weight history is used to generate a weight loss grade and questions related to amount and type of food intake are also graded. The symptom section includes nutrition impact symptoms and the fourth section assesses activities and function. These four sections can be filled in by the patient. The PG-SGA includes a physical examination focusing on fat and muscle is used to account for body composition, and several factors contributing to catabolic drive are assessed including comorbid conditions, age, cancer stage, the presence of fever, and corticosteroid use. Impact is only assessed by performance status.
The assessment is extensive but relatively time consuming and staff have to be trained to perform the assessment. The PG-SGA has been validated in cancer patients and correlates closely with quality of life. The PG-SGA carries prognostic value in advanced cancer [14 ] .
Mini nutritional assessment
The MNA includes BMI, weight loss and calf circumference as anthropometric measurement, food intake is assessed but not nutritional impact symptoms. There is no section to assess the underlying disease for catabolic drive, but there are questions about physical and psychological impact. The MNA does not include laboratory values and it is quick and efficient to use. Recently it has been validated in lung cancer patients [15] .
Malnutrition-screening tool
The MST is an easy to use screening tool and combines questions regarding recent unintentional weight loss and appetite. There is no question about the underlying disease or the impact of malnutrition. The MST requires action in terms of dietician referral or monitoring. MST is an acceptable nutrition-screening tool. The MST is validated in oncology inpatients and outpatients [16 ] .
Malnutrition universal screening tool
The MUST is the screening tool of the Malnutrition Advisory Group, of the British Association for parenteral and enteral nutrition. Three criteria are used to determine the overall risk for malnutrition, for stores depletion it assess unintentional weight loss and current weight status using BMI and for nutritional intake there is a question about acute disease that hampered nutritional intake for more than 5 days.
Each parameter can be rated and overall risk for malnutrition is calculated. All three criteria are predictors of clinical outcome, and together the three criteria are better predictors than each by itself. Because it is easy to use, the MUST is an often-used screening tool for patients in general practice. It is not specific for cancer and only covers two domains [17 ] .
Nutritional risk screening-2002
Kondrup et al. [18] developed the NRS-2002 as a screening tool for malnutrition. It is widely used in hospitals in Europe. The NRS-2002 builds on the MUST scores and a score for the severity of disease is added. Age contributes to the score if the patient is at least 70 years old.
There is no question about impact. The NRS-2002 classifies the patient's nutritional status in four categories whether artificial feeding is required [19 ] .
Cachexia assessment: current situation and challenges
The current malnutrition assessment tools are helpful to screen for malnutrition in healthcare and these tools are utilized to recommend nutritional support but they do not guide multimodal cachexia therapy. In clinical practice, a comprehensive cachexia assessment instrument that covers all domains and classifies patients into stages is needed (Table 1) .
New research findings support the view that the history of weight loss and namely the starting point of an individual patient are more important than the actual status of weight loss [9] . The PG-SGA does assess pre-illness weight and the extent of weight loss between 2 and 6 months and whether weight loss is ongoing. The PG-SGA and the MNA use anthropometric surrogates, but none of the assessment tools assess muscularity, and therefore, all of the tools failed to detect sarcopene obese patients. There is no easy to perform and widely available measurement method. For muscle mass measurement anthropometry, computed tomography, dual energy radiograph, MRI of the thigh or bioelectrical impedance are proposed, also clinical anthropometric measures such as mid-arm circumference.
Malnutrition assessment instruments measure current nutritional intake (perceived amount, type, frequencies).
In clinical practice, there are reversible and nonreversible factors for impaired oral nutritional intake; therefore, a judgment of reversibility of secondary nutrition impact symptoms seems crucial. The likelihood that a cancer patient can improve nutritional intake after treatment of S-NIS, such as inappropriately relieved pain, shortness of breath, constipation or mucositis, is not assessed in most of these instruments. The symptom list in the PG-SGA includes some of the S-NIS, but neither specifies their relative importance in deteriorating oral nutritional intake nor judges their reversibility by palliative cancer care management. The PG-SGA included symptom list does not distinguish between S-NIS symptoms and primary cachexia associated symptoms (e.g., early satiety, anorexia, or taste abnormalities), even though a sharp distinction is not possible [20 ] .
There are hardly any measurements to assess the catabolic drive and only the more extensive instruments include an assessment of the underlying disease.
The possibility to influence the underlying disease, the specific cancer by antineoplastic interventions is not part of any of the assessment tools, even although the stage and prognosis of the cancer disease affects the decision whether to provide nutritional support to the patients and whether anticachexia interventions will have a fair benefit.
It is obvious that patients with cachexia due to cancer will have a chance to reverse cachexia if the tumor is controlled, either by extrapolating response rates of tumor size and/or of metabolic drive of the tumor [21] . Only the extensive cachexia assessment instrument like the PG-SGA includes metabolic stress. Even although there is a relationship between patient reported outcomes and tumor size response as recently summarized, these data only refer to subjective assessment of patients' quality of life in selected tumor situations [22] . There are several prognostication tools in use in palliative care, but most of them include anorexia or weight loss as items and are therefore difficult to combine with malnutrition assessment tools, or are based on physicians estimation [23] .
The malnutrition assessment tools only marginally assess the impact of cachexia, whether physical or psychosocial, although this is what matters for the patients and their families.
Some of the instruments include performance status, others ask about depression, but functional impairment caused by cachexia and eating-related distress is not part of the established tools.
Current research and developments
Up-to-date cachexia assessment tools are in the process of development and validation.
The EPCRC is working on an assessment instrument limited to cancer patients based on the EPCRC classification [5 ] . The EAPC RN is conducting an international prospective data collection in large representative patient samples, in order to validate the assessment and classification systems for pain, cachexia and other symptoms (http://www.ntnu.edu/prc/projects). The Cachexia Score (CASCO) has been recently introduced to stage cachexia based on the generic cachexia definition. This score adds and weights five different factors, body weight and lean body mass loss; anorexia; inflammatory, immunological, and metabolic disturbances; physical performance; and quality of life. The score ranges from 0 to 100, mild cachexia (less than 25); moderate (more than 26 and less than50); severe (more than 51 and less than 75); and terminal phase (more than 76 and up to 100). It is intended to be used in all types of underlying disease and validation of the score is planned [24 ] .
The CASCO is based on the generic cachexia definition and encompasses the proposed domains; however, it includes high-end biochemical investigations like plasma levels of interleukins 6 and 2, blood triglyceride analyses, which are far from being used routinely in clinics. The domains are weighted unequally without sound justification and the score is based on a not easy to perform calculation. However, the score classifies cachectic patients and is intended to guide cachexia therapy.
The society of sarcopenia, cachexia and wasting disorders is defining Standards for Clinical Trials in Cancer Cachexia (www.kenes.com/mascc/Scientific/.../nutrition wkshpagenda2011 athens.pdf).
The EORTC (European Organization for Research and Treatment of Cancer) is developing a module dealing with the quality of life aspects of involuntary weight loss and cancer cachexia. This module is intended to complement the many scales in existence that measure the severity of cachexia, with a focus on the psychosocial consequences of cachexia. It is supposed to be suitable for use in clinical trials, as it will measure the impact of involuntary weight loss and cachexia for the patient (http://groups.eortc.be/qol/qolg_projects.htm#cachexia).
Several initiatives aim to improve cachexia assessment. Rather than developing new tools, it is important to agree on common basic assessment variables in order to validate them. Validation of whole assessment instruments is the next step. A stepwise approach for screening purposes, for clinical practice, and for research may be helpful.
Collaborations are required to strengthen these validation processes.
Conclusion
The new definition of cancer cachexia is based on ongoing muscle loss, which can manifest as weight loss.
Common malnutrition assessment tools are validated for the cancer patient but do not fulfil all requirements in clinic and research to assess and classify cachexia. Comprehensive cachexia assessment lays the basis for treatment decisions. Specific cachexia validated assessment instruments are awaited.
